Stock analysts at StockNews.com assumed coverage on shares of Athersys (NASDAQ:ATHX – Get Rating) in a research note issued on Thursday. The brokerage set a “sell” rating on the biopharmaceutical company’s stock.
Separately, Alliance Global Partners began coverage on Athersys in a research note on Monday, March 6th. They issued a “buy” rating and a $5.50 price objective for the company.
Athersys Price Performance
Shares of NASDAQ:ATHX opened at $1.31 on Thursday. The company has a market capitalization of $14.42 million, a PE ratio of -0.17 and a beta of -0.74. The business has a fifty day moving average price of $1.50 and a two-hundred day moving average price of $1.45. Athersys has a 1 year low of $0.50 and a 1 year high of $33.25.
Institutional Inflows and Outflows
Athersys, Inc engages in the discovery and development of therapies designed to extend and enhance to quality of human life. It offers MultiStem as its stem cell product which provides biological potency and therapeutic effects for distinct diseases and conditions in the cardiovascular, neurological, inflammatory, and immune disease areas.
- Get a free copy of the StockNews.com research report on Athersys (ATHX)
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
- Europe Raises Interest Rates, Should the Fed Follow?
Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.